Roivant Sciences (NASDAQ:ROIV) Issues Earnings Results

Roivant Sciences (NASDAQ:ROIV) posted its quarterly earnings results on Monday. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04, Zacks reports. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $10.79 on Tuesday. The stock has a market capitalization of $7.85 billion, a price-to-earnings ratio of 1.91 and a beta of 1.25. The firm’s 50 day simple moving average is $11.51 and its 200-day simple moving average is $11.60. Roivant Sciences has a 12 month low of $9.76 and a 12 month high of $13.06.

Insider Activity at Roivant Sciences

In related news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was bought at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the acquisition, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. The trade was a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the sale, the chief operating officer now directly owns 606,525 shares of the company’s stock, valued at $6,865,863. This represents a 14.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,942,629 shares of company stock worth $23,034,486 in the last three months. Company insiders own 7.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ROIV. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, November 13th. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.